14-6-11　ⓔ文献

  1. Conlon PJ, Jefferies F, et al: Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol, 1998; 49: 96–101.

  2. Satoskar AA, Suleiman S, et al: Staphylococcus Infection–Associated GN – Spectrum of IgA Staining and Prevalence of ANCA in a Single–Center Cohort. Clin J Am Soc Nephrol, 2017; 12: 39–49.

  3. Nolan CM, Abernathy RS: Nephropathy associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia. Arch Intern Med, 1977; 137: 997–1000.

  4. Koya D, Shibuya K, et al: Successful recovery of infective endocarditis–induced rapidly progressive glomerulonephritis by steroid therapy combined with antibiotics: a case report. BMC Nephrol, 2004; 5: 18.

  5. Ross MJ, Bruggeman LA, et al: Microcyst formation and HIV–1 gene expression occur in multiple nephron segments in HIV–associated nephropathy. J Am Soc Nephrol, 2001; 12: 2645–2651.

  6. Razzak Chaudhary S, Workeneh BT, et al: Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus–associated nephropathy. Nephrol Dial Transplant, 2015; 30: 1734-1740.

  7. Berliner AR, Fine DM, et al: Observations on a cohort of HIV–infected patients undergoing native renal biopsy. Am J Nephrol, 2008; 28: 478–486.

  8. Husain M, Gusella GL, et al: HIV–1 Nef induces proliferation and anchorage–independent growth in podocytes. J Am Soc Nephrol, 2002; 13: 1806–1815.

  9. Dickie P, Roberts A, et al: Focal glomerulosclerosis in proviral and c–fms transgenic mice links Vpr expression to HIV–associated nephropathy. Virology, 2004; 322: 69–81.

  10. Lescure FX, Flateau C, et al: HIV–associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant, 2012; 27: 2349–2355.

  11. Bige N, Lanternier F, et al: Presentation of HIV–associated nephropathy and outcome in HAART–treated patients. Nephrol Dial Transplant, 2012; 27: 1114–1121.

  12. Atta MG, Choi MJ, et al: Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV–associated nephropathy. Am J Med, 2005; 118: 1288.

  13. Foy MC, Estrella MM, et al: Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV–associated nephropathy. Clin J Am Soc Nephrol, 2013; 8: 1524–1532.

  14. Atta MG, Gallant JE, et al: Antiretroviral therapy in the treatment of HIV–associated nephropathy. Nephrol Dial Transplant, 2006; 21: 2809–2813.

  15. Wei A, Burns GC, et al: Long–term renal survival in HIV–associated nephropathy with angiotensin–converting enzyme inhibition. Kidney Int, 2003; 64: 1462–1471.

  16. Post FA, Campbell LJ, et al: Predictors of renal outcome in HIV–associated nephropathy. Clin Infect Dis, 2008; 46: 1282–1289.